2 years ago

T-Therapeutics Secures $48 Million Series A Funding for TCR Therapeutics

  • T-Therapeutics, a Cambridge, UK-based biotechnology company developing TCR therapeutics, raised $48M in Series A funding

  • The round was led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital (CIC) with participation from Sanofi Ventures and the University of Cambridge Venture Fund

  • The company intends to use the funds to discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders

  • Led by CEO Allan Bradley, T-Therapeutics is a T cell receptor (TCR) company spun off from the University of Cambridge

  • It is developing ‘optimal’ TCR based therapeutics using the proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of antigen-specific human TCRs.

      • ProblemHealthcare

      "Many cancers and autoimmune diseases lack effective treatments, leaving patients with limited options."

      Solution

      "T-Therapeutics develops novel T cell receptor (TCR) therapeutics using its proprietary OpTiMus® platform, which leverages a fully humanized TCR mouse to create an almost unlimited source of antigen-specific human TCRs for various targets."

      Covered on